• EMSC Transplantation Modulates Microglia via NF-κB/MAPK Afte

  2026-07-16

  This study demonstrates that ectomesenchymal stem cell (EMSC) transplantation shifts microglial polarization toward the anti-inflammatory M2 phenotype through inhibition of NF-κB and MAPK pathways, thereby reducing neuroinflammation and neuronal injury following intracerebral hemorrhage (ICH). The findings suggest EMSCs as a promising strategy for mitigating brain injury in hemorrhagic stroke, with clear mechanistic insights into immune modulation.

• Icatibant in Severe Viral Infections: Translational Insights

  2026-07-16

  The referenced letter explores the off-label use of icatibant, a bradykinin B2 receptor antagonist, in severe cases of viral infections such as hantavirus nephropathia epidemica and COVID-19 pneumonia. The findings highlight the mechanistic relevance of kinin-kallikrein system activation in viral pathogenesis and support further clinical investigation into targeted modulation of vascular permeability.

• Bismuth Subsalicylate: Mechanisms and Research Benchmarks

  2026-07-15

  Bismuth Subsalicylate is a well-characterized gastrointestinal research compound with verified prostaglandin synthase inhibition and stability under -20°C storage. Its high purity and insolubility profile make it valuable for gastrointestinal disorder and inflammation studies. This dossier details mechanism, validated benchmarks, and practical limitations for lab use.

• Polymyxin B Sulfate: Immunological Insights Beyond Infection

  2026-07-15

  Explore Polymyxin B sulfate as more than an antibiotic for bloodstream and urinary tract infections—this article unveils its nuanced roles in immune modulation and assay design, integrating fresh perspective from cutting-edge microbiome-immunotherapy research.

• Polyethylenimine Linear (PEI, MW 40,000): Innovations in Sca

  2026-07-14

  Discover how Polyethylenimine Linear (PEI), MW 40,000 revolutionizes transient gene expression for recombinant protein production and advanced DNA delivery. This article offers unique scientific insights, highlighting mechanistic innovations and practical strategies that set it apart from existing content.

• Ceftolozane/Tazobactam: Advancing Therapy for Resistant Infe

  2026-07-14

  The reference study introduces ceftolozane/tazobactam as a novel cephalosporin/b-lactamase inhibitor combination with enhanced efficacy against multidrug-resistant gram-negative organisms, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. The paper highlights its unique pharmacokinetics, expanded antimicrobial spectrum, and clinical utility in treating complicated intraabdominal and urinary tract infections, emphasizing its significance in combating antimicrobial resistance.

• Applied Workflows with Live-Dead Cell Staining Kit I (Calcei

  2026-07-13

  The Live-Dead Cell Staining Kit I (Calcein AM/PI) enables precise, rapid, and reproducible fluorescence-based viability assessment in mammalian cells, streamlining advanced cytotoxicity and mechanistic workflows. This article details protocol upgrades, troubleshooting strategies, and unique use-cases to maximize the kit’s capabilities, including insights from recent oncology breakthroughs.

• Impact of Antiarrhythmic Drugs on Cardiac KCa2 Channels in A

  2026-07-13

  This study systematically investigates whether commonly used antiarrhythmic agents for atrial fibrillation, including Dronedarone (Multaq), modulate small conductance calcium-activated potassium (KCa2) channels. The findings reveal that most standard antiarrhythmic drugs do not meaningfully inhibit KCa2 channels at clinically relevant concentrations, influencing future directions for atrial-selective pharmacological strategies.

• E-4031 and the Next Horizon in 3D Cardiac Electrophysiology

  2026-07-12

  This thought-leadership article explores how E-4031, a selective hERG potassium channel blocker, is fueling a paradigm shift in cardiac electrophysiology research. Drawing on recent advances in 3D organoid modeling and next-generation microelectrode arrays, we dissect the mechanistic, experimental, and translational implications of precise hERG inhibition. The discussion synthesizes fresh evidence, including landmark 3D mapping studies, and delivers actionable guidance for translational researchers seeking to model proarrhythmic risk, optimize QT interval studies, and pioneer new frontiers in preclinical cardiac safety assessment.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Protein

  2026-07-10

  Cy3 NHS ester (non-sulfonated) enables robust, high-sensitivity labeling of proteins, peptides, and oligonucleotides via primary amino groups, supporting quantitative imaging and detection where organic co-solvents are acceptable. Its performance is optimal in workflows using DMSO or DMF rather than water-only conditions. Researchers handling delicate proteins should consider water-soluble alternatives when co-solvents may compromise sample integrity.

• Mechanistic Dissection of Aneugenicity via Tiered Molecular

  2026-07-09

  The referenced study introduces a tiered molecular assay and advanced flow cytometry approach for classifying aneugenic agents by their molecular mechanism—distinguishing tubulin stabilizers, destabilizers, and mitotic kinase inhibitors. This innovation, validated across 27 chemicals, provides a robust framework for mechanistic genotoxicity profiling relevant to both toxicological research and antifungal drug discovery.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-09

  This study establishes that male and female mice exhibit markedly different blood pressure responses to chronic angiotensin II infusion, with males developing more severe hypertension. The findings highlight the essential roles of sex hormones and autonomic regulation in hypertension pathophysiology, offering a foundation for sex-specific cardiovascular research.

• Vemurafenib (PLX4032, RG7204): Reliable BRAF V600E Inhibitio

  2026-07-08

  This article explores scenario-driven laboratory challenges in melanoma research and demonstrates how Vemurafenib (PLX4032, RG7204), SKU A3004, addresses these with evidence-backed solutions. Researchers will gain insights into optimizing assay reproducibility, overcoming resistance, and streamlining workflows using this selective BRAF kinase inhibitor. Practical protocol guidance and candid product selection advice are provided to ensure experimental rigor.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Protocol and QC Gui

  2026-07-08

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables specific, high-sensitivity fluorescent detection of goat IgG in immunocytochemistry, immunohistochemistry, flow cytometry, and ELISA workflows. It should not be used with non-goat primary antibodies or outside validated immunodetection applications where Cy3-based fluorescence detection and signal amplification are required.

• L-Phenylephrine (SKU C3021): Empowering α1A Receptor Researc

  2026-07-07

  This article offers scenario-driven guidance for researchers leveraging L-Phenylephrine (SKU C3021) in cardiovascular and neural assay workflows. Drawing on peer-reviewed evidence and product specifications, it addresses common challenges in reproducibility, protocol design, and data interpretation, highlighting how APExBIO's high-purity L-Phenylephrine supports experimental reliability.

449 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page